Article Text

Download PDFPDF
Expanding the indications for cardiac resynchronisation therapy
  1. Cheuk-Man Yu,
  2. Fang Fang
  1. Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
  1. Correspondence to Professor Cheuk-Man Yu, Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, and Institute of Vascular Medicine, Li Ka Shing Institute of Health Sciences, S.H. Ho Cardiovascular Disease and Stroke Centre, Heart Education And Research Training (HEART) Centre, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR, China; cmyu{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Cardiac resynchronisation therapy (CRT) was first introduced for clinical use in 1996 and has been approved for treatment of heart failure (HF) and incorporated into guidelines for almost a decade. However, the question of deciding who will benefit most from this treatment remains open and numerous studies have described a spectrum from ‘super-responders’ to an apparent total lack of improvement or even deterioration of symptoms.1 Other issues are the relative lack of hard evidence for benefit from CRT in patients with QRS between 120 and 150 ms,2 the impact of residual myocardial contractile function on the improvement of left ventricular (LV) function after CRT,3 and the role of systolic dyssynchrony-guided placement of LV lead.4 The latest European Society of Cardiology (ESC) guideline for chronic HF patients recommended that for patients with LV ejection fraction (EF) ≤35% and in New York Heart Association (NYHA) Class III and IV, CRT is indicated for those with a prolonged QRS duration of ≥120 ms with left branch bundle block (LBBB) QRS morphology (Class I, Level of Evidence: A) or a QRS duration of ≥150 ms irrespective of QRS morphology (Class IIa, Level of Evidence: A). For patients with NYHA Class II, CRT is recommended for patients with EF ≤30% and a QRS duration of ≥130 ms with LBBB QRS morphology (Class I, Level of Evidence: A) or a QRS duration of ≥150 ms irrespective of QRS morphology (Class IIa, Level of Evidence: A).5 Of note, these patients should be expected to survive for >1 year. In spite of the general acceptance of the use of CRT for these specific HF subpopulations, it is possible that this therapy could be used in a wider range of patients as well as fine tuning the selection criteria to improve overall outcome.

Narrow QRS and coexisting systolic dyssynchrony

HF patients with narrow QRS complexes (commonly …

View Full Text


  • Contributors Both authors drafted the text, C-MY revised the text critically and both authors approved the final version of this text.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Data sharing statement The manuscript submitted has not been under consideration elsewhere, and none of the contents have been previously published in part or in whole in any language.